pre-update Archives

On-Demand Webinar

PBPK Modeling of Tizanidine Systemic Exposure by CYP1A2 Modulation: Impact of DDIs & Smoking

This webinar was presented on 2021 年 6 月 30 日 by David R. Taft, Ph.D. Professor, Pharmaceutics,…

Certara2021 年 7 月 26 日

视频

What is BaseCase?

Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…

Certara2021 年 7 月 20 日

On-Demand Webinar

开源建模工具：火上浇油 vs. 平息争论

The paper “Opening a Debate on Open-Source Modelling Tools: Pouring Fuel on Fire vs. Extinguishing…

Certara2021 年 7 月 15 日

Blog

确保抗体-药物偶联物开发最大概率获得成功的关键考虑事项

Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…

Certara2021 年 7 月 8 日

Video

会见 Certara 监管运营专家

Meet Rachel Bombara, Sr. Regulatory Operations Specialist at Certara. In this brief video Rachel shares…

Certara2021 年 7 月 2 日

Blog

Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations

This is the second of three blog posts discussing best practices for developing oligonucleotide therapeutics.…

Certara2021 年 6 月 25 日

Press Coverage

Fundamentals of regulatory writing: the document development process

Regulatory writers lead the development of high-quality regulatory documents by working incollaboration with colleagues across…

Certara2021 年 6 月 22 日

Blog

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

Certara2021 年 6 月 18 日

Blog

Watershed Moment for the Future of Cell Therapy Development – FDA Advisory Committee Meeting

Every FDA Advisory Committee meeting is unique, and the Cellular, Tissue, and Gene Therapies Advisory…

Certara2021 年 6 月 15 日

Brochure

推动具有影响力的科学成果从实验室走向市场

Learn how Certara drives impactful science.

Certara2021 年 6 月 14 日

pre-update

PBPK Modeling of Tizanidine Systemic Exposure by CYP1A2 Modulation: Impact of DDIs & Smoking

What is BaseCase?

开源建模工具：火上浇油 vs. 平息争论

确保抗体-药物偶联物开发最大概率获得成功的关键考虑事项

会见 Certara 监管运营专家

Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations

Fundamentals of regulatory writing: the document development process

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

Watershed Moment for the Future of Cell Therapy Development – FDA Advisory Committee Meeting

推动具有影响力的科学成果从实验室走向市场

订阅时事通讯

快捷链接

解决方案

联系我们